CX3CR1 Antibody [G13H18] | Primary Antibodies

Application: Reactivity: Human, Mouse, Rat

Usage Information

Dilution
WB1:500-1:1000 IF1:500

Application
WB, IF

Reactivity
Human, Mouse, Rat

Source
Rabbit Monoclonal Antibody

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
40 kDa 52 kDa
^*Why do the predicted and actual molecular weights differ? The following reasons may explain differences between the predicted and actual protein molecular weight. Post-translational modifications(e.g., phosphorylation, glycosylation); Splice variants and isoforms; Relative charge; Multimerization.

Datasheet & SDS

Biological Description

Specificity
CX3CR1 Antibody [G13H18] detects endogenous levels of total CX3CR1 protein.

Clone
G13H18

Synonym(s)
Beta chemokine receptor-like 1, C-X3-C CKR-1, CMK-BRL-1, CMK-BRL1, Cx3c, CX3C chemokine receptor 1, V28, CCRL1, CMKBRL1, CMKDR1, CX3CR1, GPR13, GPRV28, Rbs11, V28

Background
CX3CR1 is a seven‑transmembrane G protein–coupled chemokine receptor of the CX3C family that serves as the cognate receptor for fractalkine/CX3CL1 and is expressed on selected immune and parenchymal cell populations, including monocytes, macrophages, microglia, subsets of CD8⁺ T cells, NK cells, and smooth muscle cells. The receptor binds both membrane‑anchored and soluble CX3CL1, with the N‑terminal chemokine domain of CX3CL1 engaging the extracellular loops of CX3CR1, while the transmembrane helices and intracellular loops couple to heterotrimeric G proteins and downstream signaling modules typical of chemokine GPCRs. CX3CR1 activation by membrane‑bound CX3CL1 promotes firm adhesion of CX3CR1‑positive leukocytes to endothelial or epithelial cells under flow, integrating chemokine receptor signaling with integrin activation and cytoskeletal rearrangements to stabilize immune cell–tissue contacts at sites of inflammation or in steady‑state surveillance niches. Soluble CX3CL1 binding to CX3CR1 triggers chemotactic signaling through Gαi‑dependent pathways, leading to inhibition of adenylyl cyclase, activation of PI3K and small GTPases, and reorganization of the actin cytoskeleton that supports directed migration of monocytes, T cells, NK cells, and other CX3CR1‑expressing subsets toward fractalkine gradients. CX3CL1–CX3CR1 engagement also activates survival and activation pathways in CX3CR1⁺ cells, including PI3K–Akt and ERK cascades, and influences expression of cytokines, cytotoxic mediators, and adhesion molecules, linking this axis to cell retention, effector differentiation, and resistance to apoptosis in tissue‑resident and circulating immune populations. In the nervous system, CX3CR1 on microglia and neuron‑associated macrophages binds neuronal CX3CL1 and participates in neuron–glia communication that regulates microglial activation state, synaptic pruning, and inflammatory responses to injury or neurodegeneration. Across inflammatory and infectious contexts, the CX3CL1–CX3CR1 axis coordinates leukocyte recruitment, adhesion, and positioning within tissues and contributes to the balance between protective immunity and chronic inflammation in diseases such as atherosclerosis, autoimmune disorders, and chronic infections. CX3CR1 also appears on CX3CR1⁺ CD8⁺ T cells enriched for effector and memory‑like features, where CX3CL1 binding supports their tissue homing, retention in inflamed or tumor sites, and participation in antitumor cytotoxic responses, making CX3CR1 a marker of highly functional cytotoxic T‑cell subsets. Genetic variation or dysregulated expression of CX3CR1 associates with altered susceptibility or progression in cardiovascular, neuroinflammatory, and malignant diseases, consistent with its central role in controlling leukocyte trafficking, survival, and effector function through fractalkine‑dependent chemotactic and adhesive signaling.

Background

CX3CR1 is a seven‑transmembrane G protein–coupled chemokine receptor of the CX3C family that serves as the cognate receptor for fractalkine/CX3CL1 and is expressed on selected immune and parenchymal cell populations, including monocytes, macrophages, microglia, subsets of CD8⁺ T cells, NK cells, and smooth muscle cells. The receptor binds both membrane‑anchored and soluble CX3CL1, with the N‑terminal chemokine domain of CX3CL1 engaging the extracellular loops of CX3CR1, while the transmembrane helices and intracellular loops couple to heterotrimeric G proteins and downstream signaling modules typical of chemokine GPCRs. CX3CR1 activation by membrane‑bound CX3CL1 promotes firm adhesion of CX3CR1‑positive leukocytes to endothelial or epithelial cells under flow, integrating chemokine receptor signaling with integrin activation and cytoskeletal rearrangements to stabilize immune cell–tissue contacts at sites of inflammation or in steady‑state surveillance niches. Soluble CX3CL1 binding to CX3CR1 triggers chemotactic signaling through Gαi‑dependent pathways, leading to inhibition of adenylyl cyclase, activation of PI3K and small GTPases, and reorganization of the actin cytoskeleton that supports directed migration of monocytes, T cells, NK cells, and other CX3CR1‑expressing subsets toward fractalkine gradients. CX3CL1–CX3CR1 engagement also activates survival and activation pathways in CX3CR1⁺ cells, including PI3K–Akt and ERK cascades, and influences expression of cytokines, cytotoxic mediators, and adhesion molecules, linking this axis to cell retention, effector differentiation, and resistance to apoptosis in tissue‑resident and circulating immune populations. In the nervous system, CX3CR1 on microglia and neuron‑associated macrophages binds neuronal CX3CL1 and participates in neuron–glia communication that regulates microglial activation state, synaptic pruning, and inflammatory responses to injury or neurodegeneration. Across inflammatory and infectious contexts, the CX3CL1–CX3CR1 axis coordinates leukocyte recruitment, adhesion, and positioning within tissues and contributes to the balance between protective immunity and chronic inflammation in diseases such as atherosclerosis, autoimmune disorders, and chronic infections. CX3CR1 also appears on CX3CR1⁺ CD8⁺ T cells enriched for effector and memory‑like features, where CX3CL1 binding supports their tissue homing, retention in inflamed or tumor sites, and participation in antitumor cytotoxic responses, making CX3CR1 a marker of highly functional cytotoxic T‑cell subsets. Genetic variation or dysregulated expression of CX3CR1 associates with altered susceptibility or progression in cardiovascular, neuroinflammatory, and malignant diseases, consistent with its central role in controlling leukocyte trafficking, survival, and effector function through fractalkine‑dependent chemotactic and adhesive signaling.

References
https://pubmed.ncbi.nlm.nih.gov/33391453/ https://pubmed.ncbi.nlm.nih.gov/39377122/

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%